Cargando…

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines

The important role played by CD8(+) T lymphocytes in the control of parasitic and viral infections, as well as tumor development, has raised the need for the development of adjuvants capable of enhancing cell-mediated immunity. It is well established that protective immunity against liver stages of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez-Aseguinolaza, Gloria, Van Kaer, Luc, Bergmann, Cornelia C., Wilson, James M., Schmieg, John, Kronenberg, Mitchell, Nakayama, Toshinori, Taniguchi, Masaru, Koezuka, Yasuhiko, Tsuji, Moriya
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2002
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193764/ https://www.ncbi.nlm.nih.gov/pubmed/11877484 http://dx.doi.org/10.1084/jem.20011889

Ejemplares similares

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using Cd1d Tetramers
por: Matsuda, Jennifer L., et al.
Publicado: (2000)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells
por: Kitamura, Hidemitsu, et al.
Publicado: (1999)

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
por: Akutsu, Yasunori, et al.
Publicado: (2002)

Activation of Natural Killer T Cells Potentiates or Prevents Experimental Autoimmune Encephalomyelitis
por: Jahng, Alex W., et al.
Publicado: (2001)

Natural Killer T Cell Activation Protects Mice Against Experimental Autoimmune Encephalomyelitis
por: Singh, Avneesh K., et al.
Publicado: (2001)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues
por: Janssens, Jonas, et al.
Publicado: (2017)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

Production of α-Galactosylceramide by a Prominent Member of the Human Gut Microbiota
por: Wieland Brown, Laura C., et al.
Publicado: (2013)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

CD1d-restricted Recognition of Synthetic Glycolipid Antigens by Human Natural Killer T Cells
por: Spada, Franca M., et al.
Publicado: (1998)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo
por: Kakimi, Kazuhiro, et al.
Publicado: (2000)

Inhibition of T Helper Cell Type 2 Cell Differentiation and Immunoglobulin E Response by Ligand-Activated Vα14 Natural Killer T Cells
por: Cui, Junqing, et al.
Publicado: (1999)

Immune Privilege: Keeping an Eye on Natural Killer T Cells
por: Hong, Seokmann, et al.
Publicado: (1999)

Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity
por: Van Kaer, Luc, et al.
Publicado: (2018)

Immunization and Infection Change the Number of Recombination Activating Gene (Rag)-Expressing B Cells in the Periphery by Altering Immature Lymphocyte Production
por: Nagaoka, Hitoshi, et al.
Publicado: (2000)

A Multifactorial Mechanism in the Superior Antimalarial Activity of α-C-GalCer
por: Schmieg, John, et al.
Publicado: (2010)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
por: Shimizu, Kanako, et al.
Publicado: (2007)

Contribution of lipid-reactive natural killer T cells to obesity-associated inflammation and insulin resistance
por: Wu, Lan, et al.
Publicado: (2013)

Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
por: Toyoda, Takahide, et al.
Publicado: (2020)

Organ-specific features of natural killer cells
por: Shi, Fu-Dong, et al.
Publicado: (2011)

Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice
por: Khan, Arshad, et al.
Publicado: (2017)

Antigen specificity of invariant natural killer T-cells
por: Birkholz, Alysia M., et al.
Publicado: (2015)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Glucosylceramide and galactosylceramide, small glycosphingolipids with significant impact on health and disease
por: Reza, Safoura, et al.
Publicado: (2021)

Activation of Invariant NKT Cells with Glycolipid Ligand α-Galactosylceramide Ameliorates Glucose-6-Phosphate Isomerase Peptide-Induced Arthritis
por: Horikoshi, Masanobu, et al.
Publicado: (2012)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141(+) Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8(+) T Cell Response in Human Immune System Mice
por: Huang, Jing, et al.
Publicado: (2020)

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses
por: Zhang, Lianjun, et al.
Publicado: (2017)

Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer
por: Wu, Chao-Chih, et al.
Publicado: (2013)

Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice
por: Uchida, Takahiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3knakl2m1jgk03u2ko78b4dmfp